2007
Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S, Santin AD. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology 2007, 106: 513-520. PMID: 17540437, DOI: 10.1016/j.ygyno.2007.04.028.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityCervical cancer cell linesPeripheral blood lymphocytesComplement-dependent cytotoxicityCancer cell linesEGFR-1Cervical cancerCervical tumorsRecurrent sitesPrimary cervical cancer cell linesCell linesRecurrent/metastatic diseaseTumor cell linesType 1 receptor expressionFlow cytometryFactor type 1 receptorMetastatic cervical cancerCervical cancer patientsType 1 receptorPresence of complementCervical tumor cell linesAttractive therapeutic strategyMetastatic diseaseCervical biopsiesMetastatic sites
2003
Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy
Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecologic Oncology 2003, 91: 231-240. PMID: 14529687, DOI: 10.1016/s0090-8258(03)00460-8.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityEarly-stage cervical cancerStage cervical cancerCervical cancer cell linesCancer cell linesCervical cancerPrimary cell linesNeu expressionPrimary cervical cancer cell linesCell linesHER-2/neu expressionSite of recurrenceInhibition of proliferationEffector cellsMetastatic lesionsIL-2Primary treatmentTumor biopsiesCellular cytotoxicityHumanized mAbOriginal tumorRecurrent sitesLow dosesFlow cytometryLow expression